The role of CD109 antigen in glioma

Leukocyte differentiation antigen CD109 (CD109) is a glycosylphosphatidylinositol (GPI)-associated cell surface antigen, belonging to the α-2 macroglobulin/C3, C4 and C5 super family complex, and is a transforming growth factor (TGF)-β/Smads co-receptor. CD109 regulates the occurrence and development of glioma and is closely related to drug resistance and recurrence of glioma. As a cell membrane protein, CD109 can be directly labeled by specific antibodies or enzymes, and may also be recognized by targeted vectors for drug delivery, which is expected to become an effective diagnostic molecular marker and pharmacological therapeutic target.